Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG

NCT02916979 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Leukemia, Lymphoid
Leukemia, Myeloid
Myelodysplastic Syndromes
Myelofibrosis
Lymphoma, Malignant
Multiple Myeloma
Waldenstrom Macroglobulinemia

Interventions

DRUG: Fludarabine
DRUG: Busulfan
BIOLOGICAL: Rabbit ATG
DRUG: Methotrexate

Sponsor

Dartmouth-Hitchcock Medical Center